Phaseline

Companies › InventVacc Biologicals

InventVacc Biologicals: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Infectious disease; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Haemophilus influenzae serotype a vaccine candidate
Glycoconjugate vaccine against Haemophilus influenzae serotype a
–Phase 2Haemophilus InfluenzaeFeb 2027
Haemophilus influenzae type a (Hia) glycoconjugate vaccine
Glycoconjugate vaccine against Haemophilus influenzae serotype A
–Phase 1Haemophilus Influenzae Meningitis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06465420Haemophilus influenzae type a (Hia) glycoconjugate vaccinePhase 1Haemophilus Influenzae MeningitisInfectious diseaseOct 2024
NCT07743008Haemophilus influenzae serotype a vaccine candidatePhase 2Haemophilus InfluenzaeInfectious diseaseFeb 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Aimei Vacin BioPharm (Zhejiang) Biothervax Shenzhen Shenxin Biotechnology OsteoRemedies Jiangsu ProteLight Pharmaceutical & Biotechnology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.